Novavax Inc Quick Ratio (NVAX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Novavax inc   (NASDAQ: NVAX)

Novavax Inc 's Quick Ratio

NVAX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 2.18 below Novavax Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 85 other companies have achieved higher Quick Ratio than Novavax Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 974 to 1206.

Explain Quick Ratio?
How much Cash & cash equivalents NVAX´s has?
What are NVAX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVAX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -15.05 % -18.88 % -60.16 % -63.6 % -66.39 %
Y / Y Cash & cash equivalent Change 17.48 % 8.05 % -20.37 % -16.12 % -41.66 %
Quick Ratio MRQ 2.18 2.31 1.6 1.77 1.57
NVAX's Total Ranking # 1206 # 974 # 757 # 904 # 1047
Seq. Current Liabilities Change -3.47 % -25.54 % 7 % 10.47 % -7.82 %
Seq. Cash & cash equivalent Change -8.98 % 7.52 % -3.65 % 24.59 % -16.29 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 86
Healthcare Sector # 483
Overall Market # 1206


Quick Ratio Statistics
High Average Low
12.87 3.55 0.32
(Mar 31 2020)   (Jun 30 2023)




Financial Statements
Novavax Inc 's Current Liabilities $ 331 Millions Visit NVAX's Balance sheet
Novavax Inc 's Cash & cash equivalent $ 719 Millions Visit NVAX's Balance sheet
Source of NVAX's Sales Visit NVAX's Sales by Geography


Cumulative Novavax Inc 's Quick Ratio

NVAX's Quick Ratio for the trailling 12 Months

NVAX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -50.33 % -58.59 % -60.42 % -49.87 % -37.88 %
Y / Y Cash & cash equivalent TTM Growth -5.31 % -19.73 % -15.49 % 0.72 % 15.52 %
Quick Ratio TTM 1.92 1.79 1.67 1.26 1.01
Total Ranking TTM # 3900 # 3059 # 2476 # 2512 # 2713
Seq. Current Liabilities TTM Growth -3.61 % -4.69 % -28.99 % -23.87 % -19.63 %
Seq. Cash & cash equivalent TTM Growth 3.69 % 2.07 % -6.21 % -4.62 % -12.1 %

Quick ratio ranking by company, industry and sector >> Back to NVAX Financial Strength Comparisons >> Go to Compare NVAX Quick Ratio to its Competitors

On the trailing twelve months basis NVAX Cash & cash equivalent increased by 17.48 % in Q2 2026 year on year, while Current Liabilities decreased to $331 millions, this led to increase in in Novavax Inc 's Quick Ratio to 1.92, Quick Ratio remained below NVAX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Novavax Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3059 to 3900.

Explain Quick Ratio?
How much Cash & cash equivalents NVAX´s has?
What are NVAX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 142
Healthcare Sector # 888
Within the Market # 3900


trailing twelve months Quick Ratio Statistics
High Average Low
9.59 3.35 0.36
(Sep 30 2015)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Repligen Corp  5.94 $ 810.449  Millions$ 136.403  Millions
Cabaletta Bio Inc   5.64 $ 225.101  Millions$ 39.910  Millions
Revolution Medicines Inc   5.54 $ 3,937.969  Millions$ 710.589  Millions
Humacyte Inc   5.35 $ 79.903  Millions$ 14.948  Millions
Invivyd Inc   5.16 $ 160.080  Millions$ 31.028  Millions
Lineage Cell Therapeutics Inc   5.13 $ 50.855  Millions$ 9.914  Millions
Alector Inc   5.05 $ 172.798  Millions$ 34.236  Millions
Atyr Pharma Inc   5.04 $ 57.418  Millions$ 11.396  Millions
Vericel Corporation  5.04 $ 264.531  Millions$ 52.532  Millions
Inhibrx Biosciences Inc   4.75 $ 133.344  Millions$ 28.064  Millions
Replimune Group Inc   4.57 $ 195.328  Millions$ 42.767  Millions
Recursion Pharmaceuticals Inc   4.55 $ 545.683  Millions$ 119.886  Millions
Prime Medicine Inc   4.50 $ 142.720  Millions$ 31.692  Millions
Immunitybio inc   4.50 $ 357.371  Millions$ 79.392  Millions
Dbv Technologies S a   4.37 $ 174.900  Millions$ 40.000  Millions
Metagenomi Therapeutics Inc   4.37 $ 120.700  Millions$ 27.632  Millions
Alpha Cognition Inc.  4.37 $ 41.443  Millions$ 9.493  Millions
Intensity Therapeutics Inc   4.23 $ 9.500  Millions$ 2.245  Millions
Ginkgo Bioworks Holdings Inc   4.15 $ 302.163  Millions$ 72.740  Millions
Dyadic International Inc   4.13 $ 16.047  Millions$ 3.883  Millions
Tenaya Therapeutics Inc   4.11 $ 78.100  Millions$ 19.021  Millions
Vir Biotechnology Inc   4.08 $ 530.522  Millions$ 130.177  Millions
Adaptive Biotechnologies Corporation  3.92 $ 344.255  Millions$ 87.712  Millions
Immunocore Holdings Plc  3.74 $ 880.211  Millions$ 235.198  Millions
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions
Exozymes Inc   3.49 $ 5.653  Millions$ 1.618  Millions
Acumen Pharmaceuticals Inc   3.44 $ 160.954  Millions$ 46.848  Millions
Century Therapeutics inc   3.29 $ 49.642  Millions$ 15.068  Millions
Adma Biologics Inc   3.26 $ 136.020  Millions$ 41.690  Millions
Tscan Therapeutics Inc   3.23 $ 100.156  Millions$ 30.964  Millions

Date modified: 2026-09-08T13:57:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.